Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial | Cardiology | JAMA

This randomized clinical trial examines the safety of the exclusion of aspirin as part of an antithrombotic regimen including a vitamin K antagonist with a full

Related Keywords

Willebrand ,Nordrhein Westfalen ,Germany ,Werfen ,Kazakhstan ,Boston ,Massachusetts ,United States ,Canada ,Berlin ,Italy ,Australia ,United Kingdom ,Czech Republic ,France ,Austria ,Michigan ,America ,Mandeepr Mehra , ,Bristol Myers Squibb ,Astrazeneca ,Pagani ,Abbott Inc ,Medtronic ,University Of Michigan ,Vascular Center ,Almac Group ,Abiomed ,Us Bureau Of Labor Statistics ,Novartis ,Pfizer ,Group Information ,Heartware Ventricular Assist Device ,Antiplatelet Removal ,Hemocompatibility Events With ,North America ,End Point ,Secondary End Point ,Bend Points ,Labor Statistics ,Level Questionnaire ,Aspirin Effect ,Size Assessment ,Survival Free ,Nonsurgical Bleeding Events ,Hospital Heart ,Advanced Heart Disease ,Drs Mehra ,Interest Disclosures ,Berlin Heart ,Abbott Training ,Zoll Circulation ,